New cancer drugs threaten to stretch PBS thin
24 September, 2013 by Dylan Bushell-EmblingAdvancements in fighting cancer are also driving up the cost of cancer drugs, which could present a major strain on PBS resources, according to Flinders University’s Michael Sorich.
Bioniche to raise $10m through equity offer
20 September, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) has launched a $10m capital raising in Canada to ensure it has funds to continue development of cancer treatment Urocidin while it sells its animal health unit.
Creative prize for early-career researchers
19 September, 2013Applications are open for The Centenary Institute Lawrence Creative Prize for early-career biomedical researchers.
Viralytics meets primary goal of melanoma trial
19 September, 2013 by Dylan Bushell-EmblingA phase II trial of Viralytics' (ASX:VLA) Cavatak cancer-targeting virus in late-stage melanoma is still recruiting patients but has already met its primary endpoint.
New government, no science portfolio
17 September, 2013The incoming ministry for the newly elected Australian Government has been unveiled.
Patrys antibody gets orphan drug status in myeloma
12 September, 2013 by Dylan Bushell-EmblingPatrys's (ASX:PAB) anticancer antibody, PAT-SM6, has been granted orphan drug designation in the EU for bone marrow cancer multiple myeloma.
Starpharma developing new chemotherapy formulation
11 September, 2013 by Dylan Bushell-EmblingStarpharma (ASX:SPL) will advance dendrimer-oxaliplatin into development, after lab trials indicate its version of the chemotherapy drug can be more effective and reduces toxicity.
Viralytics cleared to begin UK cancer trial
11 September, 2013 by Dylan Bushell-EmblingThe UK's MHRA has given its final approval for a phase I/II study of Viralytics' oncolytic virus in melanoma, prostate, lung or metastatic bladder cancers.
ResMed completes recruitment for heart failure trial
06 September, 2013 by Dylan Bushell-EmblingResMed (ASX:RMD) has signed up all 1325 patients for what it is billing as the world's largest study of sleep-disordered breathing therapy in at-risk heart failure patients.
A new CEO for Dendright
05 September, 2013Brisbane-based biotech Dendright has appointed Helen Roberts as CEO.
Telesso to raise $6.5m to fund acne drug trial
04 September, 2013 by Dylan Bushell-EmblingShell company Telesso (ASX:TEO) aims to raise up to $6.5m to help support its plan to acquire Mimetica, take on the company's name and fund phase II trials for Mimetica's acne drug candidate.
GI Dynamics extends Australian reach of EndoBarrier
03 September, 2013 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) said five new centres in Australian capital cities have agreed to offer EndoBarrier as a treatment option for type 2 diabetes and obesity.
GTG signs with new US PPO for BREVAGen
22 August, 2013Genetic Technologies (ASX:GTG) has arranged for insurance claims for its BREVAGen breast cancer risk test to be adjudicated in-network with an eighth US PPO.
Prima cleared to extend cancer trial to Korea
22 August, 2013 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has received approval to extend its CANVAS cancer vaccine study to South Korea, the first Asian country to be involved in the phase II/III trial.
Sitting too much?
22 August, 2013Findings of the 12-year AusDiab follow-up study show that Australians aren’t making the lifestyle changes needed to address obesity, high blood pressure and diabetes.
